Metaphore Biotechnologies seeks to mimic nature with $50M for autoimmune, immunology drugs out of Flagship
Flagship Pioneering has churned out another biotech startup that taps into nature’s seemingly endless supply of insights and, like many new life sciences companies, is equipping its lab with machine learning to fine-tune its platform.
After years behind the scenes at the biotech incubator, Metaphore Biotechnologies is out with an initial $50 million from Flagship to mimic nature and go after whatever targets it sees fit. The lofty goal matches the vision set forth by other Flagship startups initially led by Metaphore CEO Lovisa Afzelius; these include Apriori Bio and Alltrna.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
